|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
06160 BEONE MEDICINES
Nominal 
182.300 +4.700 (+2.646%) | 2025/12 - Final USD(K$) | %Chg (Compare to Final) | 2024/12 USD(K$) | 2023/12 USD(K$) | 2022/12 USD(K$) | 2021/12 USD(K$) | |
| Turnover | 5,343,033 | 40.228% | 3,810,241 | 2,458,779 | 1,415,921 | 1,176,283 |
| Cost of Sales | (668,540) | 12.532% | (594,089) | (379,920) | (286,475) | -- |
| Gross Profit | 4,674,493 | 45.344% | 3,216,152 | 2,078,859 | 1,129,446 | -- |
| 2025/12 - Final USD(K$) | %Chg (Compare to Final) | 2024/12 USD(K$) | 2023/12 USD(K$) | 2022/12 USD(K$) | 2021/12 USD(K$) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | (42,553) | 236.707% | (12,638) | 307,891 | (223,852) | 15,904 | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | 416,854 | -- | (533,001) | (825,836) | (1,961,037) | (1,438,588) | |
| Taxation | (129,921) | 16.224% | (111,785) | (55,872) | (42,778) | (19,228) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 0 | 0 | 0 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 286,933 | -- | (644,786) | (881,708) | (2,003,815) | (1,457,816) | |
| 2025/12 - Final USD(K$) | %Chg (Compare to Final) | 2024/12 USD(K$) | 2023/12 USD(K$) | 2022/12 USD(K$) | 2021/12 USD(K$) | |
| Net Finance Costs / (Income) | (12,271) | -74.348% | (47,836) | (152,382) | (126,714) | 2,229 |
| Depreciation & Amortisation | 141,686 | -17.510% | 171,762 | 87,675 | 66,278 | 46,457 |
| Directors' Emoluments | -- | -- | 27,473 | 25,515 | 24,838 | 26,142 |
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | 20.000 | -- | -47.000 | -65.000 | -149.000 | -121.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | 0.795 | -- | (0.103) | (0.853) | (1.116) | (1.077) |
| NBV per share ($) | 2.831 | -- | 2.406 | 2.611 | 3.243 | 4.606 |
| Remarks: | Real time quote last updated: 06/03/2026 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K$) | USD 286,933 |
| %Change | -- |
| EPS / (LPS) | USD 0.200 |
| NBV Per Share ($) | USD 2.831 |